BIOMAT Database Logo BIOMAT Database Logo

Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain. 1990

P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Department of Molecular Genetics Research, Eli Lilly and Company, Indianapolis, Indiana 46285.

To study structure/function relationships of tissue plasminogen activator (t-PA) activity, one of the simplest modified t-PA structures to activate plasminogen in a fibrin-dependent manner was obtained by constructing an expression vector that deleted amino acid residues 4-175 from the full-length sequence of t-PA. The expression plasmid was introduced into a Syrian hamster cell line, and stable recombinant transformants, producing high levels of the modified plasminogen activator, were isolated. The resulting molecule, mt-PA-6, comprising the second kringle and serine protease domains of t-PA, produced a doublet of plasminogen activator activity having molecular masses of 40 and 42 kDa. The one-chain mt-PA-6 produced by cultured Syrian hamster cells was purified in high yield by affinity and size exclusion chromatography. The purified mt-PA-6 displayed the same two types of microheterogeneity observed for t-PA. NH2-terminal amino acid sequencing demonstrated that one-chain mt-PA-6 existed in both a GAR and a des-GAR form. Purified mt-PA-6 also existed in two glycosylation forms that accounted for the 40- and 42-kDa doublet of activity produced by the cultured Syrian hamster cells. Separation of these two forms by hydrophobic interaction chromatography and subsequent tryptic peptide mapping demonstrated that both forms contained N-linked glycosylation at Asn448; in addition, some mt-PA-6 molecules were also glycosylated at Asn184. Plasmin treatment of one-chain mt-PA-6 converted it to a two-chain molecule by cleavage of the Arg275-Ile276 bond. This two-chain mt-PA-6, like t-PA, had increased amidolytic activity. The fibrinolytic specific activities of the one- and two-chain forms of mt-PA-6 were similar and twice that of t-PA. The plasminogen activator activity of one-chain mt-PA-6 was enhanced greater than 80-fold by CNBr fragments of fibrinogen, and the one-chain enzyme lysed human clots in vitro in a dose-dependent manner. The ability to produce and purify a structurally simple plasminogen activator with desirable fibrinolytic properties may aid in the development of a superior thrombolytic agent for the treatment of acute myocardial infarction.

UI MeSH Term Description Entries
D007438 Introns Sequences of DNA in the genes that are located between the EXONS. They are transcribed along with the exons but are removed from the primary gene transcript by RNA SPLICING to leave mature RNA. Some introns code for separate genes. Intervening Sequences,Sequences, Intervening,Intervening Sequence,Intron,Sequence, Intervening
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene

Related Publications

P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
1H NMR structural characterization of a recombinant kringle 2 domain from human tissue-type plasminogen activator.
November 1989, Biochemistry,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Purification and characterization of tissue plasminogen activator kringle-2 domain expressed in Escherichia coli.
February 1989, Biochemistry,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator.
August 1991, Biochemical and biophysical research communications,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2.
April 2005, Arteriosclerosis, thrombosis, and vascular biology,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Ligand binding to the tissue-type plasminogen activator kringle 2 domain: structural characterization by 1H-NMR.
March 1995, Biochemistry,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
August 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution.
January 1992, Biochemistry,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Expression, purification, and characterization of the recombinant kringle 1 domain from tissue-type plasminogen activator.
April 1992, Archives of biochemistry and biophysics,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Kringle-2 domain of the tissue-type plasminogen activator. 1H-NMR assignments and secondary structure.
April 1991, European journal of biochemistry,
P J Burck, and D H Berg, and M W Warrick, and D T Berg, and J D Walls, and S R Jaskunas, and R M Crisel, and B Weigel, and C J Vlahos, and D B McClure
Characterization of the acidic oligosaccharides assembled on the Pichia pastoris-expressed recombinant kringle 2 domain of human tissue-type plasminogen activator.
October 1997, Biotechnology and applied biochemistry,
Copied contents to your clipboard!